pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2021-31-3-365-373pulmo-2373Research ArticleКЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯCLINICAL PHARMACOLOGYНовая тройная комбинация беклометазона дипропионата, гликопиррония бромида и формотерола фумарата в лечении хронической обструктивной болезни легкихNew triple combination of beclomethasone dipropionate, glycopyrronium bromide and formoterol fumarate in the treatment of chronic obstructive pulmonary diseasehttps://orcid.org/0000-0002-5999-2150АвдеевС. Н.AvdeevS. N.

Авдеев Сергей Николаевич – д. м. н., член-корр. Российской академии наук, профессор, заведующий кафедрой пульмонологии Федерального государственного автономного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет), ведущий научный сотрудник Федерального государственного бюджетного учреждения «Научно-исследовательский институт пульмонологии» Федерального медико-биологического агентства

119991, Москва, ул. Трубецкая, 8, стр. 2115682, Москва, Ореховый бульвар, 28тел.: (495) 708-35-76

Sergey N. Avdeev, Doctor of Medicine, Professor, Corresponding Member of Russian Academy of Sciences, Head of Department of Pulmonology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University); Leading Researcher, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia

ul. Trubetskaya 8, build. 2, Moscow, 119991Orekhovyy bul’var 28, Moscow, 115682tel.: (495) 708-35-76

serg_avdeev@list.ruhttps://orcid.org/0000-0002-0685-4133ТрушенкоН. В.TrushenkoN. V.

Трушенко Наталья Владимировна – к. м. н., ассистент кафедры пульмонологии Федерального государственного автономного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет), научный сотрудник научно-методического центра мониторинга и контроля болезней органов дыхания Федерального государственного бюджетного учреждения «Научно-исследовательский институт пульмонологии» Федерального медико-биологического агентства

119991, Москва, ул. Трубецкая, 8, стр. 2115682, Москва, Ореховый бульвар, 28тел.: (495) 708-35-76

Natalia V. Trushenko, Candidate of Medicine; Assistant Lecturer, Department of Pulmonology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University); Researcher, Scientific and Methodological Center for Monitoring and Control of Respiratory Diseases, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia

ul. Trubetskaya 8, build. 2, Moscow, 119991Orekhovyy bul’var 28, Moscow, 115682tel.: (495) 708-35-76

trushenko.natalia@yandex.ruФедеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет); Федеральное государственное бюджетное учреждение «Научно-исследовательский институт пульмонологии» Федерального медико-биологического агентстваРоссияI.M. Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia; Federal Pulmonology Research Institute, Federal Medical and Biological Agency of RussiaRussian Federation202110062021313365373Copyright © Авдеев С.Н., Трушенко Н.В., 20212021Авдеев С.Н., Трушенко Н.В.Avdeev S.N., Trushenko N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2373

Терапевтические возможности лечения хронической обструктивной болезни легких (ХОБЛ) за последние годы существенно расширились, в первую очередь – за счет появления новых комбинированных препаратов. Одной из часто используемых терапевтических опций, применяемых для лечения пациентов с частыми обострениями ХОБЛ, является тройная комбинация, включающая длительно действующие β2-агонисты, длительно действующие антихолинергические препараты и ингаляционные глюкокортикостероиды, однако при назначении такой терапии врачи зачастую сталкиваются со снижением не только приверженности пациентов терапии, но и ее эффективности, при этом отмечается увеличение риска нежелательных явлений. В статье представлена актуальная на сегодняшний день информация по клинической эффективности и профилю безопасности фиксированной тройной комбинации беклометазона дипропионата, гликопиррония бромида и формотерола фумарата, доступной в форме экстрамелкодисперсного аэрозоля, с помощью которой появилась возможность оптимизировать ингаляционную терапию у пациентов с частыми обострениями ХОБЛ.

Therapeutical options for the treatment of chronic obstructive pulmonary disease (COPD) have significantly expanded in recent years, primarily due to market entry of new combination drugs. One of the commonly used therapeutic options for patients with frequent exacerbations of COPD is a triple combination, including LABA, LAMA and ICS, however, prescribing such therapy, doctors often face a decrease in treatment adherence, which ultimately leads to lack of effectiveness, as well as with an increased risk of adverse events. This article presents the current information on the clinical efficacy and safety profile of a fixed triple combination of beclomethasone dipropionate, glycopyrronium bromide and formoterol fumarate, available as extrafine aerosol inhaler, allows to optimize inhalation treatment for patients with frequent exacerbations of COPD.

хроническая обструктивная болезнь легкихтройная терапиякомбинированные препаратыингаляционные глюкокортикостероидыбеклометазона дипропионатгликопиррония бромидформотерола фумаратchronic obstructive pulmonary diseasetriple therapycombined drugsinhaled glucocorticosteroidsbeclomethasone dipropionateglycopyrroniumformoterolПубликация осуществлена при поддержке компании «Кьези Фармасьютикалс».This publication is supported by Chiesi Pharmaceuticals LLC company.ReferencesAisanov Z., Avdeev S., Arkhipov V. et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int. J. COPD. 2018; 13: 183–187. DOI: 10.2147/COPD.S153770.Aisanov Z., Avdeev S., Arkhipov V. et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int. J. COPD. 2018; 13: 183–187. DOI: 10.2147/COPD.S153770.Hogg J.C., Chu F., Utokaparch S. et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350 (26): 2645–2653. DOI: 10.1056/NEJMoa032158.Hogg J.C., Chu F., Utokaparch S. et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350 (26): 2645–2653. DOI: 10.1056/NEJMoa032158.Higham A., Quinn A.M., Cançado J.E.D., Singh D. The pathology of small airways disease in COPD: historical aspects and future directions. Respir. Res. 2019; 20 (1): 49. DOI: 10.1186/s12931-0191017-y.Higham A., Quinn A.M., Cançado J.E.D., Singh D. The pathology of small airways disease in COPD: historical aspects and future directions. Respir. Res. 2019; 20 (1): 49. DOI: 10.1186/s12931-0191017-y.Авдеев С.Н., Трушенко Н.В. Тройная терапия в лечении хронической обструктивной болезни легких. Пульмонология. 2019; 29 (2): 199–206. DOI: 10.18093/0869-0189-2019-29-2-199-206.Avdeev S.N., Trushenko N.V. [Triple therapy in chronic obstructive pulmonary disease]. Pul’monologiya. 2019; 29 (2): 199–206. DOI: 10.18093/0869-0189-2019-29-2-199-206 (in Russian).Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2021. Available at: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdfGlobal Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2021. Available at: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdfHersh C.P., Washko G.R., Estépar R.S.J. et al. Paired inspiratory-expiratory chest CT scans to assess for small airways disease in COPD. Respir. Res. 2013; 14 (1): 42. DOI: 10.1186/1465-9921-14-42.Hersh C.P., Washko G.R., Estépar R.S.J. et al. Paired inspiratory-expiratory chest CT scans to assess for small airways disease in COPD. Respir. Res. 2013; 14 (1): 42. DOI: 10.1186/1465-9921-14-42.Crisafulli E., Pisi R., Aiello M. et al. Prevalence of small-airway dysfunction among COPD patients with different GOLD stages and its role in the impact of disease. Respiration. 2017; 93 (1): 32–41. DOI: 10.1159/000452479.Crisafulli E., Pisi R., Aiello M. et al. Prevalence of small-airway dysfunction among COPD patients with different GOLD stages and its role in the impact of disease. Respiration. 2017; 93 (1): 32–41. DOI: 10.1159/000452479.Suissa S., Dell’Aniello S., Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir. Med. 2018; 6 (11): 855–862. DOI: 10.1016/S2213-2600(18)30368-0.Suissa S., Dell’Aniello S., Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir. Med. 2018; 6 (11): 855–862. DOI: 10.1016/S2213-2600(18)30368-0.Lipson D.A., Barnhart F., Brealey N. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018; 378 (18): 1671–1680. DOI: 10.1056/NEJMoa1713901.Lipson D.A., Barnhart F., Brealey N. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018; 378 (18): 1671–1680. DOI: 10.1056/NEJMoa1713901.Авдеев С.Н., Невзорова В.А., Куделя Л.М. и др. Вопросы тройной терапии в лечении хронической обструктивной болезни легких. Комментарии к алгоритму. Резолюция Совета экспертов от 13.06.18 (Владивосток). Пульмонология. 2019; 29 (3): 365–374. DOI: 10.18093/0869-0189-2019-29-3-365-374.Avdeev S.N., Nevzorova V.A., Kudelya L.M. et al. [Issues of triple therapy of chronic obstructive pulmonary disease. Comments to the algorithm. A resolution of expert panel, June 13, 2018, Vladivostok]. Pul’monologiya. 2019; 29 (3): 365–374. DOI: 10.18093/0869-0189-2019-29-3-365-374.Singh D., Corradi M., Spinola M. et al. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. Int. J. COPD. 2017; 12: 2917–2928. DOI: 10.2147/COPD.S146822.Singh D., Corradi M., Spinola M. et al. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. Int. J. COPD. 2017; 12: 2917–2928. DOI: 10.2147/COPD.S146822.Vestbo J., Papi A., Corradi M. et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017; 389 (10082): 1919–1929. DOI: 10.1016/S0140-6736(17)30188-5.Vestbo J., Papi A., Corradi M. et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017; 389 (10082): 1919–1929. DOI: 10.1016/S0140-6736(17)30188-5.Papi A., Vestbo J., Fabbri L. et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018; 391 (10125): 1076–1084. DOI: 10.1016/S0140-6736(18)30206-X.Papi A., Vestbo J., Fabbri L. et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018; 391 (10125): 1076–1084. DOI: 10.1016/S0140-6736(18)30206-X.Georges G., Zheng J.P., Li Z. et al. Effect of extra-fine triple therapy with beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) pressurized metered dose inhaler (PMDI) on exacerbatioms in East Asian patients with COPD: the TRIVERSYTI study. Chest. 2020; 158 (4, Suppl.): A1785–1786. DOI: 10.1016/j.chest.2020.08.1557.Georges G., Zheng J.P., Li Z. et al. Effect of extra-fine triple therapy with beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) pressurized metered dose inhaler (PMDI) on exacerbatioms in East Asian patients with COPD: the TRIVERSYTI study. Chest. 2020; 158 (4, Suppl.): A1785–1786. DOI: 10.1016/j.chest.2020.08.1557.Koo H.K., Vasilescu D.M., Booth S. et al. Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study. Lancet Respir. Med. 2018; 6 (8): 591–602. DOI: 10.1016/S2213-2600(18)30196-6.Koo H.K., Vasilescu D.M., Booth S. et al. Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study. Lancet Respir. Med. 2018; 6 (8): 591–602. DOI: 10.1016/S2213-2600(18)30196-6.Usmani O.S. Treating the small airways. Respiration. 2012; 84 (6): 441–453. DOI: 10.1159/000343629.Usmani O.S. Treating the small airways. Respiration. 2012; 84 (6): 441–453. DOI: 10.1159/000343629.De Backer W., Devolder A., Poli G. et al. Lung deposition of BDP/ formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J. Aerosol. Med. Pulm. Drug Deliv. 2010; 23 (3): 137–148. DOI: 10.1089/jamp.2009.0772.De Backer W., Devolder A., Poli G. et al. Lung deposition of BDP/ formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J. Aerosol. Med. Pulm. Drug Deliv. 2010; 23 (3): 137–148. DOI: 10.1089/jamp.2009.0772.Singh D., Fabbri L.M., Corradi M. et al. Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation. Eur. Respir. J. 2019; 53 (5): 1900235. DOI: 10.1183/13993003.00235-2019.Singh D., Fabbri L.M., Corradi M. et al. Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation. Eur. Respir. J. 2019; 53 (5): 1900235. DOI: 10.1183/13993003.00235-2019.De Backer J.W., Vos W.G., Vinchurkar S.C. et al. Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. Radiology. 2010; 257 (3): 854–862. DOI: 10.1148/radiol.10100322.De Backer J.W., Vos W.G., Vinchurkar S.C. et al. Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. Radiology. 2010; 257 (3): 854–862. DOI: 10.1148/radiol.10100322.Kappeler D., Sommerer K., Kietzig C. et al. Lung deposition of fluticasone propionate/formoterol administered via a breath-triggered inhaler. Eur. Respir J. 2017; 50 (Suppl. 61): PA522. DOI:10.1183/1393003.congress-2017.PA522.Kappeler D., Sommerer K., Kietzig C. et al. Lung deposition of fluticasone propionate/formoterol administered via a breath-triggered inhaler. Eur. Respir J. 2017; 50 (Suppl. 61): PA522. DOI:10.1183/1393003.congress-2017.PA522.Müllinger B., Brand P., Fischer A. et al. Intra-pulmonal deposition of two different tobramycin formulations. J. Cyst. Fibros. 2005; 4 (Suppl. 1): S53 (Abs. 198). Available at: https://core.ac.uk/download/pdf/82229439.pdfMüllinger B., Brand P., Fischer A. et al. Intra-pulmonal deposition of two different tobramycin formulations. J. Cyst. Fibros. 2005; 4 (Suppl. 1): S53 (Abs. 198). Available at: https://core.ac.uk/download/pdf/82229439.pdfDe Backer W., Devolder A., Poli G. et al. Lung deposition of BDP/ formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J. Aerosol. Med. Pulm. Drug Deliv. 2010; 23 (3): 137–148. DOI: 10.1089/jamp.2009.0772.De Backer W., Devolder A., Poli G. et al. Lung deposition of BDP/ formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J. Aerosol. Med. Pulm. Drug Deliv. 2010; 23 (3): 137–148. DOI: 10.1089/jamp.2009.0772.Usmani O.S., Scichilone N., Mignot B. et al. Airway deposition of extrafine inhaled triple therapy in patients with COPD: A model approach based on functional respiratory imaging computer simulations. Int. J. Chron. Obstruct. Pulmon. Dis. 2020; 15: 2433–2440. DOI: 10.2147/COPD.S269001.Usmani O.S., Scichilone N., Mignot B. et al. Airway deposition of extrafine inhaled triple therapy in patients with COPD: A model approach based on functional respiratory imaging computer simulations. Int. J. Chron. Obstruct. Pulmon. Dis. 2020; 15: 2433–2440. DOI: 10.2147/COPD.S269001.Sonnappa S., Martin R., Israel E. et al. Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids. PLoS One. 2017; 12 (6): e0178112. DOI: 10.1371/journal.pone.0178112.Sonnappa S., Martin R., Israel E. et al. Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids. PLoS One. 2017; 12 (6): e0178112. DOI: 10.1371/journal.pone.0178112.Hovelmann R., Georges G., Bahari Javan S. et al. TriOptimize VI: The use of extrafine single inhaler triple therapy improves adherence to treatment in patients with COPD – Real-world evidence. Am. J. Respir. Crit. Care Med. 2020; 201: A4303. DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A4303.Hovelmann R., Georges G., Bahari Javan S. et al. TriOptimize VI: The use of extrafine single inhaler triple therapy improves adherence to treatment in patients with COPD – Real-world evidence. Am. J. Respir. Crit. Care Med. 2020; 201: A4303. DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A4303.Vestbo J., Fabbri L., Papi A. et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur. Respir. J. 2018; 52 (6): 1801230. DOI: 10.1183/13993003.01230-2018.Vestbo J., Fabbri L., Papi A. et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur. Respir. J. 2018; 52 (6): 1801230. DOI: 10.1183/13993003.01230-2018.

The authors declare that there are no conflicts of interest present.